Zobrazeno 1 - 1
of 1
pro vyhledávání: '"COVISHIELD Study Group"'
Autor:
Prasad S. Kulkarni, Chandrasekaran Padmapriyadarshini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B. S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T. S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S. R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Rajeev Vadakkedath, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale, COVISHIELD Study Group
Publikováno v:
SSRN Electronic Journal.
Background: ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at Serum Institute of India Pvt Ltd (SIIPL) after technology transfer from AstraZeneca, was evaluated in this phase 2/3 immunobridging study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::601162143fc3340f94bb80b5413af048
https://doi.org/10.2139/ssrn.3901791
https://doi.org/10.2139/ssrn.3901791
